Alarm grew after a researcher resigned, warning that the “people building AI earnestly believe that it could kill us all by ...

A researcher at Anthropic, the company behind the AI chatbot Claude, has quit over fears that the technology will ‘kill us ...

AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Tim Rocktaschel, co-founder of Recursive Superintelligence, says his company can build recursive self-improving AI within roughly two years. Recursive Superintelligence, a London-based startup founded ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive risks persist and the company is years away from meaningful pipeline revenue. RXRX's AI-driven Recursion OS platform shows strong ...

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its ...

<li data-line="1" dir="auto"><span class="list-bullet"></span>الدرس بيشرح مفهوم <code>Recursion</code> في <code>JavaScript</code>.</li> <li data-line ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...